To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD)
Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University Sc...
Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is...
Memantine is an uncompetitive antagonist with moderate affinity for NMDA receptors, and it demonstra...
effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: ...
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lew...
Objective: To determine the effect of memantine in the treatment of Dementia with Lewy Bodies (DLB)....
International audiencePrevious studies have suggested that patients with Lewy-body-related dementias...
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
Background: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
OBJECTIVE: This 30-week extension trial was a continuation of the first double-blind randomized cont...
OBJECTIVE: Two common and characteristic sleep disturbances have been described in dementia with Lew...
Objective - In both dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), attentio...
Early use of memantine in the treatment of Lewy body dementia (LBD) is a common type of major neuroc...
Memantine protects cultured neurons from excitotoxin-induced cell-death; it attenuated loss of choli...
There are currently no FDA-approved treatments for frontotemporal lobar degeneration (FTLD). The obj...
Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University Sc...
Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is...
Memantine is an uncompetitive antagonist with moderate affinity for NMDA receptors, and it demonstra...
effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: ...
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lew...
Objective: To determine the effect of memantine in the treatment of Dementia with Lewy Bodies (DLB)....
International audiencePrevious studies have suggested that patients with Lewy-body-related dementias...
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
Background: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
OBJECTIVE: This 30-week extension trial was a continuation of the first double-blind randomized cont...
OBJECTIVE: Two common and characteristic sleep disturbances have been described in dementia with Lew...
Objective - In both dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), attentio...
Early use of memantine in the treatment of Lewy body dementia (LBD) is a common type of major neuroc...
Memantine protects cultured neurons from excitotoxin-induced cell-death; it attenuated loss of choli...
There are currently no FDA-approved treatments for frontotemporal lobar degeneration (FTLD). The obj...
Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University Sc...
Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is...
Memantine is an uncompetitive antagonist with moderate affinity for NMDA receptors, and it demonstra...
DOI
Add to ORKG